Tectonic Therapeutic (TECX) Earnings Analysis
Tectonic Therapeutic (TECX) next reports earnings on 2026-08-06, consensus EPS -1.34878 USD. Last quarter (2026-05-07) it missed with EPS -1.34 USD vs -1.16 USD est (-15.5%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -7.08.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does TECX next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -1.34878 USD |
| Revenue estimate | n/a |
TECX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -1.34 USD | -1.16 USD | -15.5% | Miss |
| 2026-02-26 | -1.03 USD | -1.11 USD | +7.2% | Beat |
| 2025-11-06 | -1.02 USD | -1.05 USD | +2.9% | Beat |
| 2025-08-07 | -1.07 USD | -0.98 USD | -9.2% | Miss |
| 2025-05-08 | -0.93 USD | -1.1 USD | +15.5% | Beat |
| 2025-03-20 | -0.84 USD | -1.39 USD | +39.6% | Beat |
| 2024-08-14 | -3.81 USD | -1.96 USD | -94.4% | Miss |
Beat rate: 4/7 (57%) over reported quarters with consensus data.
TECX valuation and analyst view
| Trailing P/E | -7.08 |
|---|---|
| Trailing EPS | -4.44808 USD |
| Price / book | 2.57 |
| Dividend yield | 0.00% |
| Market cap | 0.60B |
| Analyst consensus | Buy (5 buy / 0 hold / 0 sell) |
| Avg price target | 81 USD |
Related research pages
Frequently asked questions
When is Tectonic Therapeutic (TECX)'s next earnings date?
Tectonic Therapeutic is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -1.34878 USD.
Did TECX beat earnings last quarter?
In its 2026-05-07 report, TECX posted EPS of -1.34 USD versus a -1.16 USD estimate — a miss of 15.5%.
What is TECX's earnings track record?
Over the last 7 reported quarters with consensus data, TECX beat estimates 4 times (57%).
What is TECX's current P/E ratio and EPS?
TECX trades at a trailing P/E of -7.08 on trailing EPS of -4.4480783317005 USD.
What do analysts rate TECX?
Analyst consensus is "Buy" across 5 ratings (1 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 81 USD.